Evidence map›Paper›PMID 32294208›Full record

ArticleToxicological sciences : an official journal of the Society of Toxicology2020

Tissue-Engineered Human Myobundle System as a Platform for Evaluation of Skeletal Muscle Injury Biomarkers.

Alastair Khodabukus, Amulya Kaza, Jason Wang, Neel Prabhu, Richard Goldstein, Vishal S Vaidya, Nenad Bursac

Open access · greenAbstract read
In one paragraph

Article in Toxicological sciences : an official journal of the Society of Toxicology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 27 citations in OpenAlex.

  1. RYR1Journal of translational medicine · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Alastair KhodabukusDepartment of Biomedical Engineering, Duke University, Durham, North Carolina 27708-90281.
Amulya KazaDepartment of Biomedical Engineering, Duke University, Durham, North Carolina 27708-90281.
Jason WangDepartment of Biomedical Engineering, Duke University, Durham, North Carolina 27708-90281.
Neel PrabhuDepartment of Biomedical Engineering, Duke University, Durham, North Carolina 27708-90281.
Richard GoldsteinDrug Research and Development, Pfizer, Groton, Connecticut 06340.
Vishal S VaidyaDrug Research and Development, Pfizer, Groton, Connecticut 06340.
Nenad BursacDepartment of Biomedical Engineering, Duke University, Durham, North Carolina 27708-90281.
Duke University · USPfizer (United States) · US

Funding

Vascular, Cardiac, and Lung Alveolar Human Microphysiological Systems for SARS-CoV-2 Drug ScreeningUH3TR002142 · NCATS · DUKE UNIVERSITY · PI TRUSKEY, GEORGE A · 2019 to 2021
$4.0M
Interaction of Subchondral Bone and Articular Cartilage System with Skeletal MuscleUH3TR000505 · NCATS · DUKE UNIVERSITY · PI TRUSKEY, GEORGE A · 2014 to 2016
$3.6M
Epigenetic Mechanisms Promoting LongevityR01AG054840 · NIA · DUKE UNIVERSITY · PI KRAUS, VIRGINIA · 2018 to 2022
$3.4M
University Training Program in Biomolecular and Tissue EngineeringT32GM144291 · NIGMS · DUKE UNIVERSITY · PI Charles A. Gersbach, Tatiana Segura · 2022 to 2026
$2.6M
Systemic Inflammation in Microphysiological Models of Muscle and Vascular DiseaseUG3TR002142 · NCATS · DUKE UNIVERSITY · PI TRUSKEY, GEORGE A · 2017 to 2018
$2.1M
Microphysiological Human Tissue Systems for Monitoring of Genome Editing OutcomesU01HL156348 · NHLBI · DUKE UNIVERSITY · PI BURSAC, NENAD, GERSBACH, CHARLES A. · 2020 to 2022
$2.0M
Muscle-macrophage constructs for skeletal muscle repairR01AR070543 · NIAMS · DUKE UNIVERSITY · PI BURSAC, NENAD · 2016 to 2020
$1.9M
Translational studies of GAA deficiency in bioengineered human muscleR01AR065873 · NIAMS · DUKE UNIVERSITY · PI BURSAC, NENAD, KOEBERL, DWIGHT D · 2013 to 2017
$1.8M
Microphysiological Human Tissue Systems for Monitoring of Genome Editing OutcomesU01EB028901 · NIBIB · DUKE UNIVERSITY · PI BURSAC, NENAD, GERSBACH, CHARLES A. · 2019 to 2019
$668k
Epigenetic Mechanisms Promoting LongevityR56AG054840 · NIA · DUKE UNIVERSITY · PI KRAUS, VIRGINIA · 2017 to 2017
$515k
NCATS NIH HHS UG3 TR002142NCATS NIH HHS UH3 TR000505NCATS NIH HHS UH3 TR002142NHLBI NIH HHS U01 HL156348NIAMS NIH HHS R01 AR065873NIAMS NIH HHS R01 AR070543NIA NIH HHS R01 AG054840NIA NIH HHS R56 AG054840NIBIB NIH HHS U01 EB028901NIGMS NIH HHS T32 GM144291
6 · The paper itself

Abstract

Traditional serum biomarkers used to assess skeletal muscle damage, such as activity of creatine kinase (CK), lack tissue specificity and sensitivity, hindering early detection of drug-induced myopathies. Recently, a novel four-factor skeletal muscle injury panel (MIP) of biomarkers consisting of skeletal troponin I (sTnI), CK mass (CKm), fatty-acid-binding protein 3 (Fabp3), and myosin light chain 3, has been shown to have increased tissue specificity and sensitivity in rodent models of skeletal muscle injury. Here, we evaluated if a previously established model of tissue-engineered functional human skeletal muscle (myobundle) can allow detection of the MIP biomarkers after injury or drug-induced myotoxicity in vitro. We found that concentrations of three MIP biomarkers (sTnI, CKm, and Fabp3) in myobundle culture media significantly increased in response to injury by a known snake venom (notexin). Cerivastatin, a known myotoxic statin, but not pravastatin, induced significant loss of myobundle contractile function, myotube atrophy, and increased release of both traditional and novel biomarkers. In contrast, dexamethasone induced significant loss of myobundle contractile function and myotube atrophy, but decreased the release of both traditional and novel biomarkers. Dexamethasone also increased levels of matrix metalloproteinase-2 and -3 in the culture media which correlated with increased remodeling of myobundle extracellular matrix. In conclusion, this proof-of-concept study demonstrates that tissue-engineered human myobundles can provide an in vitro platform to probe patient-specific drug-induced myotoxicity and performance assessment of novel injury biomarkers to guide preclinical and clinical drug development studies.

Indexed as

Tissue EngineeringAnimalsAspartate AminotransferasesBiomarkersCreatine KinaseFatty Acid Binding Protein 3Fatty Acid-Binding ProteinsHumansMatrix Metalloproteinase 2Muscle ContractionMuscle Fibers, SkeletalMuscle, SkeletalMuscular DiseasesMyosin Light ChainsRats, Sprague-DawleyTroponin IAspartate AminotransferasesBiomarkersCreatine KinaseFABP3 protein, humanFatty Acid Binding Protein 3Fatty Acid-Binding ProteinsMatrix Metalloproteinase 2Myosin Light ChainsTroponin Iatrophybiomarkermusclemyopathystatintissue engineeringtoxicity

Identifiers

PMID32294208
PMCPMC7643536
OpenAlexW3016154545

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.